# EDGAR Filing Document

**Accession Number:** 0001001907
**File Stem:** 0001437749-23-003171
**Filing Date:** 2023-2
**Character Count:** 117046
**Document Hash:** 0108681fa6861433cff29e692583232f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-003171.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001437749-23-003171

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 69

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTROTECH Corp
- **CENTRAL INDEX KEY:** 0001001907
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 911273737
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34426
- **FILM NUMBER:** 23619119

**BUSINESS ADDRESS:**
- **STREET 1:** 2105 DONLEY DR. SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78758
- **BUSINESS PHONE:** 5124859530

**MAIL ADDRESS:**
- **STREET 1:** 2028 E. BEN WHITE BLVD.
- **STREET 2:** SUITE 240-9530
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78741

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASTROTECH Corp \WA\
- **DATE OF NAME CHANGE:** 20090310

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPACEHAB INC \WA\
- **DATE OF NAME CHANGE:** 19951006

astc20221231_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 10-Q**

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2022**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ___________ to ___________**

**Commission file number 001-34426**

![logo.jpg](logo.jpg)

------

**Astrotech Corporation**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **91-1273737** |
| State or Other Jurisdiction of<br> Incorporation or Organization | I.R.S. Employer Identification No. |
| **2105 Donley Drive, Suite 100, Austin, Texas** | **78758** |
| Address of Principal Executive Offices | Zip Code |

---

**(512) 485-9530**

Registrant's Telephone Number, Including Area Code

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ASTC | NASDAQ Stock Market, LLC |

---

------

[**Table of Contents**](#toc)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of February 10, 2023, the number of shares of the registrant's common stock outstanding was: 1,692,600.

------

[**Table of Contents**](#toc)

**ASTROTECH CORPORATION AND SUBSIDIARIES**

**QUARTERLY REPORT ON FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [PART I:](#part1) | [FINANCIAL INFORMATION](#part1) | [3](#part1) |
| [ITEM 1.](#item1) | [CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)](#item1) | [3](#item1) |
| [ITEM 2.](#item2) | [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#item2) | [20](#item2) |
| [ITEM 3.](#item3) | [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#item3) | [26](#item3) |
| [ITEM 4.](#item4) | [CONTROLS AND PROCEDURES](#item4) | [26](#item4) |
| [PART II:](#part2) | [OTHER INFORMATION](#part2) | [27](#part2) |
| [ITEM 1.](#part2item1) | [LEGAL PROCEEDINGS](#part2item1) | [27](#part2item1) |
| [ITEM 1A.](#part2item1a) | [RISK FACTORS](#part2item1a) | [27](#part2item1a) |
| [ITEM 2.](#part2item2) | [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#part2item2) | [27](#part2item2) |
| [ITEM 3.](#part2item3) | [DEFAULTS UPON SENIOR SECURITIES](#part2item3) | [27](#part2item3) |
| [ITEM 4.](#part2item4) | [MINE SAFETY DISCLOSURES](#part2item4) | [27](#part2item4) |
| [ITEM 5.](#part2item5) | [OTHER INFORMATION](#part2item5) | [27](#part2item5) |
| [ITEM 6.](#part2item6) | [EXHIBITS](#part2item6) | [28](#part2item6) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**PART I: FINANCIAL INFORMATION**

**ITEM 1. Condensed Consolidated Financial Statements**

**ASTROTECH CORPORATION AND SUBSIDIARIES**

**Condensed Consolidated Balance Sheets**

(In thousands, except share and per share data)

---

| | | |
|:---|:---|:---|
|  | ***December 31,*** | ***June 30,*** |
|  | ***2022*** | ***2022*** |
|  | **(Unaudited)** | **(Note)** |
| **Assets** |  |  |
| Current assets |  |  |
| Cash and cash equivalents | $15889 | $26453 |
| Short-term investments | 30953 | 26173 |
| Accounts receivable | 112 | 56 |
| &nbsp;&nbsp;&nbsp; Cost and estimated revenue in excess of billings | 4 | 2 |
| Inventory, net: |  |  |
| Raw materials | 1012 | 864 |
| Work-in-process | 167 | 136 |
| Finished goods | 318 | 518 |
| Prepaid expenses and other current assets | 979 | 748 |
| **Total current assets** | **49434** | **54950** |
| Property and equipment, net | 1554 | 1098 |
| Operating leases, right-of-use assets, net | 336 | 162 |
| Other assets, net | 11 | 11 |
| **Total assets** | $**51335** | $**56221** |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities |  |  |
| Accounts payable | 301 | 169 |
| Payroll related accruals | 711 | 816 |
| Accrued expenses and other liabilities | 965 | 961 |
| Income tax payable | 1 | 2 |
| Term note payable - related party |  | 500 |
| Lease liabilities, current | 291 | 234 |
| **Total current liabilities** | **2269** | **2682** |
| Lease liabilities, net of current portion | 356 | 303 |
| **Total liabilities** | **2625** | **2985** |
| **Commitments and contingencies (Note 13)** |  |  |
| **Stockholders' equity** |  |  |
| Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at December 31, 2022 and June 30, 2022 |  |  |
| Common stock, $0.001 par value, 250,000,000 shares authorized at December 31, 2022 and June 30, 2022; 1,690,450 and 1,685,595 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively | 190643 | 190642 |
| Additional paid-in capital | 80295 | 79505 |
| Accumulated deficit | (220659) | (215712) |
| Accumulated other comprehensive loss | (1569) | (1199) |
| **Total stockholders' equity** | **48710** | **53236** |
| **Total liabilities and stockholders' equity** | $**51335** | $**56221** |

---

*Note: The balance sheet at June 30, 2022, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.*

*See accompanying notes to unaudited condensed consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**ASTROTECH CORPORATION AND SUBSIDIARIES**

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

(In thousands, except per share data)

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Six Months Ended*** | ***Six Months Ended*** |
|  | ***December 31,*** | ***December 31,*** | ***December 31,*** | ***December 31,*** |
|  | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| Revenue | $263 | $561 | $301 | $748 |
| Cost of revenue | 155 | 441 | 187 | 616 |
| **Gross profit** | **108** | **120** | **114** | **132** |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 1558 | 1728 | 3200 | 3154 |
| Research and development | 1364 | 652 | 2492 | 1291 |
| **Total operating expenses** | **2922** | **2380** | **5692** | **4445** |
| **Loss from operations** | **(2814)** | **(2260)** | **(5578)** | **(4313)** |
| Other income and expense, net | 396 | 80 | 631 | 104 |
| **Loss from operations before income taxes** | **(2418)** | **(2180)** | **(4947)** | **(4209)** |
| Income tax benefit |  |  |  |  |
| **Net loss** | $**(2418)** | $**(2180)** | $**(4947)** | $**(4209)** |
| Weighted average common shares outstanding: |  |  |  |  |
| Basic and diluted | 1613 | 1583 | 1613 | 1582 |
| **Basic and diluted net loss per common share:** |  |  |  |  |
| Net loss per common share | $(1.50) | $(1.38) | $(3.07) | $(2.66) |
| **Other comprehensive loss, net of tax:** |  |  |  |  |
| Net loss | $(2418) | $(2180) | $(4947) | $(4209) |
| Available-for-sale securities: |  |  |  |  |
| Net unrealized losses, net of zero tax expense | (2) | (197) | (370) | (245) |
| **Total comprehensive loss** | $**(2420)** | $**(2377)** | $**(5317)** | $**(4454)** |

---

*See accompanying notes to unaudited condensed consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**ASTROTECH CORPORATION**

**Condensed Consolidated Statement of Changes in Stockholders**' **Equity**

(In thousands)

(Unaudited)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Preferred Stock*** | ***Preferred Stock*** |  |  |  |  |  |  |
|  | ***Series D*** | ***Series D*** | ***Common Stock*** | ***Common Stock*** |  |  |  |  |
|  | ***Number of Shares Outstanding*** | ***Amount*** | ***Number of Shares Outstanding*** | ***Amount*** | ***Additional Paid-In Capital*** | ***Accumulated Deficit*** | ***Accumulated Other Comprehensive Loss*** | ***Total Stockholders' Equity*** |
| **Balance at June 30, 2022** | **281** | $**—** | **1686** | $**190642** | $**79505** | $**(215712)** | $**(1199)** | $**53236** |
| Net change in available-for-sale marketable securities | *—* |  | *—* |  |  |  | (368) | (368) |
| Stock-based compensation | *—* |  | 2 |  | 387 |  |  | 387 |
| Net loss | *—* |  | *—* |  |  | (2529) |  | (2529) |
| **Balance at September 30, 2022** | **281** | $**—** | **1688** | $**190642** | $**79892** | $**(218241)** | $**(1567)** | $**50726** |
| Net change in available-for-sale marketable securities | *—* |  | *—* |  |  |  | (2) | (2) |
| Stock-based compensation |  |  | 2 | 1 | 403 |  |  | 404 |
| Net loss | *—* |  | *—* |  |  | (2418) |  | (2418) |
| **Balance at December 31, 2022** | **281** | $**—** | **1690** | $**190643** | $**80295** | $**(220659)** | $**(1569)** | $**48710** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Preferred Stock*** | ***Preferred Stock*** |  |  |  |  |  |  |
|  | ***Series D*** | ***Series D*** | ***Common Stock*** | ***Common Stock*** |  |  |  |  |
|  | ***Number of Shares Outstanding*** | ***Amount*** | ***Number of Shares Outstanding*** | ***Amount*** | ***Additional Paid-In Capital*** | ***Accumulated Deficit*** | ***Accumulated Other Comprehensive Loss*** | ***Total Stockholders' Equity*** |
| **Balance at June 30, 2021** | **281** | $**—** | **1648** | $**190641** | $**77971** | $**(207382)** | $**(23)** | $**61207** |
| Net change in available-for-sale marketable securities | *—* |  | *—* |  |  |  | (48) | (48) |
| Stock-based compensation | *—* |  | *—* |  | 359 |  |  | 359 |
| Net loss | *—* |  | *—* | **—** |  | (2029) |  | (2029) |
| **Balance at September 30, 2021** | **281** | $**—** | **1648** | $**190641** | $**78330** | $**(209411)** | $**(71)** | $**59489** |
| Net change in available-for-sale marketable securities | ***—*** |  | *—* |  |  |  | (197) | (197) |
| Stock-based compensation | **—** |  | 2 |  | 439 |  |  | 439 |
| Net loss | ***—*** |  | *—* |  |  | (2180) |  | (2180) |
| **Balance at December 31, 2021** | **281** | $— | **1650** | $**190641** | $**78769** | $**(211591)** | $**(268)** | $**57551** |

---

*See accompanying notes to unaudited condensed consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ASTROTECH CORPORATION AND SUBSIDIARIES**

**Condensed Consolidated Statements of Cash Flows**

(In thousands)

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | ***Six Months Ended*** | ***Six Months Ended*** |
|  | ***December 31,*** | ***December 31,*** |
|  | ***2022*** | ***2021*** |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(4947) | $(4209) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Stock-based compensation | 791 | 798 |
| Depreciation and amortization | 199 | 94 |
| Changes in assets and liabilities: |  |  |
| Accounts receivable | (56) | (87) |
| Cost and estimated revenue in excess of billings | (2) |  |
| Inventory, net | 21 | 86 |
| Accounts payable | 132 | (306) |
| Income tax payable | (1) |  |
| Other assets and liabilities | (392) | 140 |
| **Net cash used in operating activities** | **(4255)** | **(3484)** |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp; Purchase of security investments | (5100) |  |
| Purchases of property and equipment | (632) | (264) |
| **Net cash used in investing activities** | **(5732)** | **(264)** |
| **Cash flows from financing activities:** |  |  |
| Repayment of related party debt | (500) | (2000) |
| Repayments on lease financing | (77) | (18) |
| **Net cash used in financing activities** | **(577)** | **(2018)** |
| **Net change in cash and cash equivalents** | **(10564)** | **(5766)** |
| Cash and cash equivalents at beginning of period | 26453 | 35936 |
| **Cash and cash equivalents at end of period** | $**15889** | $**30170** |
| **Supplemental disclosures of cash flow information:** |  |  |
| Cash paid for interest | $63 | $3 |
| Acquisition of equipment through financing lease | $— | $394 |
| Operating right of use assets and associated liabilities | $223 | $— |
| Income taxes paid | $1 | $— |

---

*See accompanying notes to unaudited condensed consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**ASTROTECH CORPORATION AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements (Unaudited)**

**(*1*) General Information** 

***Description of the Company*** – Astrotech Corporation (Nasdaq: ASTC) ("Astrotech," the "Company," "we," "us," or "our"), a Delaware corporation organized in *1984,* is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology.

***Basis of Presentation*** – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do *not* include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the *three* and *six* months ended *December 31, 2022* are *not* necessarily indicative of the results that *may* be expected for the year ending *June 30, 2023*. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form *10*-K for the year ended *June 30, 2022*. Certain prior period amounts have been reclassified to conform to the current year presentation or adjusted due to rounding and have had *no* impact on net income or stockholders' equity.

***Reverse Stock Split*** – On Monday, *December 5, 2022,* the Company effectuated a reverse stock split of its shares of common stock, par value $0.001 per share (the "Common Stock"), whereby every *thirty* (*30*) pre-split shares of Common Stock were exchanged for *one* (*1*) post-split share of the Company's Common Stock (the "Reverse Stock Split"). *No* fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise have held a fractional share of the Common Stock received a cash payment in lieu thereof. Numbers presented in these condensed consolidated financial statements have been adjusted to reflect the Reverse Stock Split.

***Accounting Pronouncements*** – There were *no* new accounting pronouncements which affected the company and its business.

**Our Business Units**

***Astrotech Technologies, Inc.***

Astrotech Technologies, Inc. ("ATI") owns and licenses the Astrotech Mass Spectrometer Technology™ (the "AMS Technology"), the platform mass spectrometry technology originally developed by *1*<sup>st</sup> Detect Corporation (*"1*<sup>st</sup> Detect"). The AMS Technology has been designed to be inexpensive, smaller, and easier to use when compared to traditional mass spectrometers. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 21 patents granted with one additional patent in process along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to three wholly-owned subsidiaries of Astrotech on an exclusive basis, including to *1*<sup>st</sup> Detect for use in the security and detection market, to AgLAB Inc. ("AgLAB") for use in the agriculture market, and to BreathTech Corporation ("BreathTech") for use in breath analysis applications.

***1*<sup>st</sup> Detect Corporation***

*1*<sup>st</sup> Detect, a licensee of ATI for the security and detection market, has developed the TRACER *1000™,* the world's *first* mass spectrometry ("MS") based explosives trace detector ("ETD") certified by the European Civil Aviation Conference ("ECAC"). The TRACER *1000* was designed to outperform the ETDs currently used at airports, cargo and other secured facilities, and borders worldwide. The Company believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry ("IMS"). The Company further believes that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument's performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER *1000's* detection library does *not* degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

[**Table of Contents**](#toc)

In order to sell the TRACER *1000* to airport and cargo security customers in the European Union and certain other countries, we obtained ECAC certification. The Company is currently selling the TRACER *1000* to customers who accept ECAC certification. As of *December 31, 2022,* the Company has deployed the TRACER *1000* in approximately *21* locations in *14* countries throughout Europe and Asia.

In the United States, the Company is working with the U.S. Transportation Security Administration ("TSA") towards air cargo certification. On *March 27, 2018,* the Company announced that the TRACER *1000* was accepted into TSA's Air Cargo Screening Technology Qualification Test ("ACSQT") and, on *April 4, 2018,* the Company announced that the TRACER *1000* entered into testing with the TSA for passenger screening at airports. On *November 14, 2019,* the Company announced that the TRACER *1000* had been selected by the TSA's Innovation Task Force to conduct live checkpoint screening at Miami International Airport. With similar protocols as ECAC testing, the Company has received valuable feedback from all programs. Following ECAC certification and the Company's early traction within the cargo market, testing for cargo security continued with the TSA. With the COVID-*19* pandemic, all testing within the TSA was put on hold; however, cargo testing resumed during the summer of *2020,* and the Company subsequently announced on *September 9, 2020* that the TRACER *1000* passed the non-detection testing portion of the TSA's ACSQT. Due to delays caused by COVID-*19,* TSA cargo detection testing is ongoing, but has proceeded much more slowly than originally anticipated. As a result, efforts are primarily focused on our other opportunities. TSA cargo detection testing is the final step to be listed on the Air Cargo Screening Technology List as an "approved" device. If approved, the TRACER *1000* will be approved for cargo sales in the United States.

***AgLAB Inc.***

AgLAB, an exclusive licensee of ATI for the agriculture market, has developed the AgLAB *1000™* series of mass spectrometers for use in the hemp and cannabis markets with initial focus on optimizing yields in the distillation process. The AgLAB product line is a derivative of the Company's core AMS Technology. We believe hemp and cannabis distillers can gain significant improvement on their processing yields by utilizing the AgLAB *1000*-*D2™* system with their existing short path-molecular distillation systems. As part of our growth plan, we also plan to launch a family of "process control" methods and solutions that we believe could be valuable additions to many nutraceutical distillation laboratories.

During the *first* quarter of fiscal year *2023,* we began our *first* production run of the AgLAB *1000*-*D2* and sales efforts are currently underway.

***BreathTech Corporation***

BreathTech, an exclusive licensee of ATI for use in breath analysis applications, is developing the BreathTest-*1000™,* a breath analysis tool to screen for volatile organic compound ("VOC") metabolites found in a person's breath that could indicate they *may* have a bacterial or viral infection. The Company believes that new tools to aid in the battle against COVID-*19* and other diseases remain of the utmost importance to help more quickly identify that an infection *may* be present.

In *June 2022,* the Company expanded its existing study that initially focused on COVID-*19* with Cleveland Clinic to use the BreathTest-*1000* to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus ("RSV"), carriage of Staphylococcus aureus, and Clostridioides difficile ("C. diff") infections.

**(*2*) Investments**

The following tables summarize gains and losses related to the Company's investments as of *December 31, 2022* and *June 30, 2022*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***December 31, 2022*** | ***December 31, 2022*** | ***December 31, 2022*** | ***December 31, 2022*** |
| **Available-for-Sale Investments** | ***Adjusted*** | ***Unrealized*** | ***Unrealized*** | ***Fair*** |
| **(In thousands)** | ***Cost*** | ***Gain*** | ***Loss*** | ***Value*** |
| Mutual Funds - Corporate & Government Debt | $19997 | $— | $(1071) | $18926 |
| ETFs - Corporate & Government Debt | 7375 |  | (463) | 6912 |
| Time Deposits | 5150 |  | (35) | 5115 |
| **Total** | $**32522** | $**—** | $**(1569)** | $**30953** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***June 30, 2022*** | ***June 30, 2022*** | ***June 30, 2022*** | ***June 30, 2022*** |
| **Available-for-Sale Investments** | ***Adjusted*** | ***Unrealized*** | ***Unrealized*** | ***Fair*** |
| **(In thousands)** | ***Cost*** | ***Gain*** | ***Loss*** | ***Value*** |
| Mutual Funds - Corporate & Government Debt | $19997 | $— | $(806) | $19191 |
| ETFs - Corporate & Government Debt | 7375 |  | (393) | 6982 |
| Time Deposits |  |  |  |  |
| **Total** | $**27372** | $**—** | $**(1199)** | $**26173** |

---

We have certain financial instruments on our condensed consolidated balance sheets related to interest-bearing time deposits. Time deposits with maturities of less than *90* days, if any, from the purchase date are included in "Cash and Cash Equivalents." Time deposits with maturities from *91*-*360* days, if any, are included in "Short-term investments." Time deposits with maturities of more than *360* days, if any, are included in "Long-term investments." As of *December 31, 2022* and *June 30, 2022*, the Company had *no* long-term investments. For more information about the fair value of the Company's financial instruments, see footnote *8.*

The following table presents the carrying amounts of certain financial instruments as of *December 31, 2022* and *June 30, 2022*:

---

| | | |
|:---|:---|:---|
|  | ***Carrying Value*** | ***Carrying Value*** |
|  | ***Short-Term Investments*** | ***Short-Term Investments*** |
| **(In thousands)** | ***December 31, 2022*** | ***June 30, 2022*** |
| Mutual Funds - Corporate & Government Debt | $18926 | $19191 |
| ETFs - Corporate & Government Debt | 6912 | 6982 |
| Time Deposits - Maturities from 91-360 days | 5115 |  |
| **Total** | $**30953** | $**26173** |

---

**(*3*) Leases** 

On *April 27, 2021,* Astrotech entered into a new lease for a research and development facility of approximately 5,960 square feet in Austin, Texas (the "R&D facility") that includes a laboratory, a small production shop, and offices for staff, although many of the Company's employees continue to work remotely. The lease commenced on *June 1, 2021* and had a lease term of 36 months. On *November 11, 2022,* the Company signed a lease extension agreement for the R&D facility, extending the term of the lease through *April 30, 2025.* The Company's total contractual base rent obligation for the *eleven*-month extension is approximately $95 thousand.

On *November 22, 2022,* Astrotech entered into a sublease agreement for an additional facility directly adjacent to the R&D facility (the "subleased facility"). The subleased facility consists of approximately 3,900 square feet and will provide the space needed as the Company launches its AgLAB products and continues its R&D efforts at BreathTech. The sublease commenced on *December 1, 2022* and has a lease term of 29 months. The Company's total contractual base rent obligation for the subleased facility is approximately $156 thousand.

Operating lease assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company's leases do *not* provide an implicit rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Significant judgement is required when determining the Company's incremental borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Upon the adoption of Topic *842,* the Company's accounting for financing leases, previously referred to as capital leases, remains substantially unchanged from prior guidance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

The balance sheet presentation of the Company's operating and finance leases is as follows:

---

| | | |
|:---|:---|:---|
| **(In thousands)** | ***Classification on the Condensed Consolidated Balance Sheet*** | ***December 31, 2022*** |
| **Assets:** |  |  |
| Operating lease assets | *Operating leases, right-of-use assets, net* | $336 |
| Financing lease assets | *Property and equipment, net* | 415 |
| ***Total lease assets*** | ***Total lease assets*** | $**751** |
| **Liabilities:** |  |  |
| Current: |  |  |
| Operating lease obligations | *Lease liabilities, current* | $148 |
| Financing lease obligations | *Lease liabilities, current* | 143 |
| Non-current: |  |  |
| Operating lease obligations | *Lease liabilities, non-current* | 216 |
| Financing lease obligations | *Lease liabilities, non-current* | 140 |
| ***Total lease liabilities*** | ***Total lease liabilities*** | $**647** |

---

Future minimum lease payments under non-cancellable leases are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **(In thousands)** |  |  |  |
| **For the Year Ended June 30,** | ***Operating Leases*** | ***Financing Leases*** | ***Total*** |
| 2023 | $83 | $77 | $160 |
| 2024 | 166 | 154 | 320 |
| 2025 | 142 | 67 | 209 |
| 2026 |  |  |  |
| 2027 |  |  |  |
| Thereafter |  |  |  |
| **Total lease obligations** | **391** | **298** | **689** |
| Less: imputed interest | 27 | 15 | 42 |
| **Present value of net minimum lease obligations** | **364** | **283** | **647** |
| Less: lease liabilities - current | 148 | 143 | 291 |
| **Lease liabilities - non-current** | $**216** | $**140** | $**356** |

---

Other information as of *December 31, 2022* is as follows:

---

| | |
|:---|:---|
| Weighted-average remaining lease term (years): |  |
| Operating leases | 2.3 |
| Financing leases | 2.0 |
| Weighted-average discount rate: |  |
| Operating leases | 6.3% |
| Financing leases | 5.3% |

---

Cash payments for operating leases for the *three* months ended *December 31, 2022* and *2021* totaled $31 thousand and $25 thousand, respectively. Cash payments for financing leases for the *three* months ended *December 31, 2022* and *2021* totaled $38 thousand and $15 thousand, respectively.

Cash payments for operating leases for the *six* months ended *December 31, 2022* and *2021* totaled $57 thousand and $35 thousand, respectively. Cash payments for financing leases for the *six* months ended *December 31, 2022* and *2021* totaled $77 thousand and $18 thousand, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

**(*4*) Property and Equipment, net**

As of *December 31, 2022* and *June 30, 2022*, property and equipment, net consisted of the following:

---

| | | |
|:---|:---|:---|
| **(In thousands)** | ***December 31, 2022*** | ***June 30, 2022*** |
| Furniture, fixtures, equipment & leasehold improvements | $1981 | $1371 |
| Software | 217 | 264 |
| Capital improvements in progress | 140 | 242 |
| **Gross property and equipment** | **2338** | **1877** |
| Accumulated depreciation and amortization | (784) | (779) |
| **Property and equipment, net** | $**1554** | $**1098** |

---

Depreciation and amortization expense of property and equipment for the *three* months ended *December 31, 2022* and *2021* was $82 thousand and $34 thousand, respectively. Depreciation and amortization expense of property and equipment for the *six* months ended *December 31, 2022* and *2021* was $149 thousand and $51 thousand, respectively.

**(*5*) Stockholders**' **Equity**

***Common Stock***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On *November 22, 2022,* the Company filed a *third* amendment (the "Amendment") to the Company's Certificate of Incorporation (as amended, the "Certificate of Incorporation") with the Secretary of State of the State of Delaware to effect a *1*-for- *30* reverse stock split of all of the Company's issued and outstanding shares of Common Stock. The Amendment provided that, at the effective time of the Reverse Stock Split, every *30* shares of the Company's issued and outstanding Common Stock were automatically combined into *one* validly issued, fully paid and non-assessable share of Common Stock, without effecting a change to the par value per share. The Reverse Stock Split affected all shares of the Company's Common Stock outstanding immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of Common Stock available for issuance under the Company's equity incentive plans. In addition, the Reverse Stock Split effected a reduction in the number of shares of Common Stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in exercise price per share. The Reverse Stock Split also triggered a proportionate adjustment to the number of shares of Common Stock issuable upon the conversion of our Series D convertible preferred stock, par value of $0.001 per share ("Series D Preferred Shares"). All historical per share data, number of shares outstanding, and other common stock equivalents for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split.

 ***Preferred Stock***

The Company has issued 280,898 shares of Series D Preferred Shares, all of which are issued and outstanding. Series D Preferred Shares are convertible to common stock on a *one*-to-*thirty* basis. Series D Preferred Shares are *not* callable by the Company. The holder of the preferred stock is entitled to receive, and we shall pay, dividends on shares equal to and in the same form as dividends actually paid on shares of common stock when, and if, such dividends are paid on shares of common stock. *No* other dividends are paid on the preferred shares. Preferred shares have *no* voting rights. Upon liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary, the preferred shares have preference over common stock. The holder of Series D Preferred Shares has the option to convert said shares to common stock at the holder's discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

***Share Repurchase Program***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On *November 9, 2022,* the Company's Board of Directors authorized a share repurchase program that allows the Company to repurchase up to $1.0 million of the Company's common stock beginning *November 17, 2022* and continuing through and including *November 17, 2023.* The shares *may* be repurchased from time to time in the open market or privately negotiated transactions or by other means in accordance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including management's assessment of the intrinsic value of the Company's common stock, the market price of the Company's common stock, general market and economic conditions, available liquidity, compliance with the Company's debt and other agreements, applicable legal requirements, and other considerations. The exact number of shares to be repurchased by the Company is *not* guaranteed, and the program *may* be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases with available working capital. There were no repurchases of the Company's common stock under the share repurchase program during the *three* months ended *December 31, 2022.*

***Warrants***

A summary of the common stock warrant activity for the *six* months ended *December 31, 2022* is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Number of Shares Underlying Warrants (In thousands)*** | ***Weighted Average Exercise Price*** | ***Aggregate Fair Market Value at Issuance (In thousands)*** | ***Weighted Average Remaining Contractual Term (Years)*** |
| Outstanding June 30, 2022 | **80** | $**72.10** | $**3747** | **3.60** |
| Warrants issued |  |  |  | *—* |
| Warrants exercised |  |  |  | *—* |
| Warrants expired |  |  |  | *—* |
| Outstanding December 31, 2022 | **80** | $**72.10** | $**3747** | **3.10** |

---

The following represents a summary of the warrants outstanding at each of the dates identified:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | ***Number of Shares Underlying Warrants (In thousands)*** | ***Number of Shares Underlying Warrants (In thousands)*** |
| **Issue Date** | ***Classification*** | ***Exercise Price*** | ***Expiration Date*** | ***December 31, 2022*** | ***June 30, 2022*** |
| March 26, 2020 | *Equity* | $187.50 | *March 25, 2025* | 1 | 1 |
| March 30, 2020 | *Equity* | $140.63 | *March 27, 2025* | 2 | 2 |
| October 23, 2020 | *Equity* | $86.25 | *October 21, 2025* | 15 | 15 |
| October 28, 2020 | *Equity* | $80.63 | *October 28, 2025* | 6 | 6 |
| February 16, 2021 | *Equity* | $121.88 | *February 11, 2026* | 6 | 6 |
| April 12, 2021 | *Equity* | $56.25 | *April 7, 2026* | 50 | 50 |
| ***Total Outstanding*** | ***Total Outstanding*** |  |  | **80** | **80** |

---

***Nasdaq Compliance***

The Reverse Stock Split was primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on The Nasdaq Stock Market LLC ("Nasdaq"). On *December 19, 2022,* the Company received written notice from the Listing Qualifications Department of Nasdaq stating that, because the Company's Common Stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule *5550*(a)(*2*), and that the matter is now closed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

[**Table of Contents**](#toc)

**(*6*) Net Loss per Share**

Basic net loss per share is computed on the basis of the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed based on the weighted average number of common shares outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method and the if-converted method. Potentially dilutive common shares include outstanding stock options and share-based awards.

The following table reconciles the numerators and denominators used in the computations of both basic and diluted net loss per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Six Months Ended*** | ***Six Months Ended*** |
|  | ***December 31,*** | ***December 31,*** | ***December 31,*** | ***December 31,*** |
| **(In thousands, except per share data)** | ***2022*** | ***2021*** | ***2022*** | ***2021*** |
| **Numerator:** |  |  |  |  |
| Net loss | $(2418) | $(2180) | $(4947) | $(4209) |
| **Denominator:** |  |  |  |  |
| Denominator for basic and diluted net loss per share — weighted average common stock outstanding | 1613 | 1583 | 1613 | 1582 |
| **Basic and diluted net loss per common share:** |  |  |  |  |
| Net loss per common share | $(1.50) | $(1.38) | $(3.07) | $(2.66) |

---

All unvested restricted stock awards for the *six* months ended *December 31, 2022* are not included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive. Options to purchase 37,032 shares of common stock at exercise prices ranging from $13.20 to $175.50 per share outstanding as of *December 31, 2022* were *not* included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive.

**(*7*) Revenue Recognition** 

Astrotech recognizes revenue employing the generally accepted revenue recognition methodologies described under the provisions of Accounting Standards Codification ("ASC") Topic *606* "Revenue from Contracts with Customers" ("Topic *606"*), which was adopted by the Company in fiscal year *2019.* The methodology used is based on contract type and how products and services are provided. The guidelines of Topic *606* establish a *five*-step process to govern the recognition and reporting of revenue from contracts with customers. The *five* steps are: (i) identify the contract with a customer, (ii) identify the performance obligations within the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations within the contract, and (v) recognize revenue when or as the performance obligations are satisfied.

An additional factor is reasonable assurance of collectability. This necessitates deferral of all or a portion of revenue recognition until collection. During the *three* and *six* months ended *December 31, 2022*, the Company had *three* revenue sources that comprised materially all of its revenue. Revenue was recognized at a point in time consistent with the guidelines in Topic *606.*

*Contract Assets and Liabilities.* The Company enters into contracts to sell products and provide services, and it recognizes contract assets and liabilities that arise from these transactions. The Company recognizes revenue and corresponding accounts receivable according to Topic *606* and, at times, recognizes revenue in advance of the time when contracts give us the right to invoice a customer. The Company *may* also receive consideration, per the terms of a contract, from customers prior to transferring goods to the customer. The Company records customer deposits as deferred revenue. Additionally, the Company *may* receive payments, most typically for service and warranty contracts, at the onset of the contract and before services have been performed. In such instances, the Company records a deferred revenue liability. The Company recognizes these contract liabilities as sales after all revenue recognition criteria are met.

*Practical Expedients.* In cases where the Company is responsible for shipping after the customer has obtained control of the goods, the Company has elected to treat the shipping activities as fulfillment activities rather than as a separate performance obligation. Additionally, the Company has elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than *one* year. The Company only gives consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than *one* year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

[**Table of Contents**](#toc)

*Product Sales.* The Company recognizes revenue from sales of products upon shipment or delivery when control of the product transfers to the customer, depending on the terms of each sale, and when collection is probable. In the circumstance where terms of a product sale include subjective customer acceptance criteria, revenue is deferred until the Company has achieved the acceptance criteria unless the customer acceptance criteria are perfunctory or inconsequential. The Company generally offers customers payment terms of *60* days or less.

*Freight.* The Company records shipping and handling fees that it charges to its customers as revenue and related costs as cost of revenue.

*Multiple Performance Obligations.* Certain agreements with customers include the sale of equipment involving multiple elements in cases where obligations in a contract are distinct and thus require separation into multiple performance obligations, revenue recognition guidance requires that contract consideration be allocated to each distinct performance obligation based on its relative standalone selling price. The value allocated to each performance obligation is then recognized as revenue when the revenue recognition criteria for each distinct promise or bundle of promises has been met.

The standalone selling price for each performance obligation is an amount that depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the good or service. When there is only *one* performance obligation associated with a contract, the entire amount of consideration is attributed to that obligation. When a contract contains multiple performance obligations, the standalone selling price is *first* estimated using the observable price, which is generally a list price net of applicable discount or the price used to sell the good or service in similar circumstances. In circumstances when a selling price is *not* directly observable, the Company will estimate the standalone selling price using information available to it including its market assessment and expected cost, plus margin.

The timetable for fulfilment of each of the distinct performance obligations can range from completion in a short amount of time and entirely within a single reporting period to completion over several reporting periods. The timing of revenue recognition for each performance obligation *may* be dependent upon several milestones, including physical delivery of equipment, completion of site acceptance test, and in the case of after-market consumables and service deliverables, the passage of time.

**(*8*) Fair Value Measurement** 

ASC Topic *820* "Fair Value Measurement" ("Topic *820"*) defines fair value, establishes a market-based framework or hierarchy for measuring fair value, and expands disclosures about fair value measurements. Topic *820* is applicable whenever assets and liabilities are measured and included in the financial statements at fair value.

The fair value hierarchy established in Topic *820* prioritizes the inputs used in valuation techniques into *three* levels as follows:

Level *1* - Quoted prices in active markets for identical assets or liabilities.

Level *2* - Inputs other than Level *1* that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are *not* active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level *3* - Unobservable inputs that are supported by little or *no* market activity and are significant to the fair value of the assets or liabilities.

The following tables present the carrying amounts, estimated fair values, and valuation input levels of certain financial instruments as of *December 31, 2022* and *June 30, 2022*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***December 31, 2022*** | ***December 31, 2022*** | ***December 31, 2022*** | ***December 31, 2022*** | ***December 31, 2022*** |
|  | ***Carrying*** | ***Fair Value Measured Using*** | ***Fair Value Measured Using*** | ***Fair Value Measured Using*** | ***Fair*** |
| **(In thousands)** | ***Amount*** | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***Value*** |
| **Available-for-Sale Investments** |  |  |  |  |  |
| Short-Term Investments |  |  |  |  |  |
| Mutual Funds - Corporate & Government Debt | 18926 | 18926 |  |  | 18926 |
| ETFs - Corporate & Government Debt | 6912 | 6912 |  |  | 6912 |
| Time deposits: 91-360 days | 5115 |  | 5115 |  | 5115 |
| **Total Available-for-Sale Investments** | $**30953** | $**25838** | $**5115** | $**—** | $**30953** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***June 30, 2022*** | ***June 30, 2022*** | ***June 30, 2022*** | ***June 30, 2022*** | ***June 30, 2022*** |
|  | ***Carrying*** | ***Fair Value Measured Using*** | ***Fair Value Measured Using*** | ***Fair Value Measured Using*** | ***Fair*** |
| **(In thousands)** | ***Amount*** | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***Value*** |
| **Available-for-Sale Investments** |  |  |  |  |  |
| Short-Term Investments |  |  |  |  |  |
| Mutual Funds - Corporate & Government Debt | 19191 | 19191 |  |  | 19191 |
| ETFs - Corporate & Government Debt | 6982 | 6982 |  |  | 6982 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time deposits: 91-360 days |  |  |  |  |  |
| **Total Available-for-Sale Investments** | $**26173** | $**26173** | $**—** | $**—** | $**26173** |

---

The value of available-for-sale securities with Level *1* inputs is based on pricing from *third*-party pricing vendors, who use quoted prices in active markets for identical assets. The fair value measurements used for time deposits are considered Level *2* and use pricing from *third*-party pricing vendors who use quoted prices for identical or similar securities in both active and inactive markets.

**(*9*) Debt**

On *September 5, 2019,* the Company entered into a private placement transaction with Thomas B. Pickens III, the Chief Executive Officer and Chairman of the Board of Directors of the Company, for the issuance and sale of a secured promissory note to Mr. Pickens with a principal amount of $1.5 million (the *"2019* Note"), and on *February 13, 2020,* the Company entered into a *second* private placement transaction with Mr. Pickens for the issuance and sale of a *second* secured promissory note to Mr. Pickens with a principal amount of $1.0 million (the *"2020* Note" and, collectively with the *2019* Note, the "Original Notes"). Interest on the Original Notes accrued at 11% per annum. The principal amount and accrued interest on the Original Notes originally were to become due and payable on *September 5, 2020;* however, on *August 24, 2020,* the Company and Mr. Pickens agreed to extend the date of maturity of the Original Notes and payment of accrued interest to *September 5, 2021 (*the "Extended Maturity Date"). The Company had the option to prepay the principal amount and all accrued interest on the Original Notes at any time prior to the Extended Maturity Date.

In connection with the issuance of the Original Notes, the Company, along with *1*<sup>st</sup> Detect Corporation and Astrotech Technologies, Inc. (the "Subsidiaries"), entered into *two* security agreements, dated as of *September 5, 2019* and *February 13, 2020 (*collectively, the "Original Security Agreements"), with Mr. Pickens, pursuant to which the Company and the Subsidiaries granted to Mr. Pickens a security interest in all of the Company's and the Subsidiaries' Collateral, as such term is defined in the Original Security Agreements. In addition, the Subsidiaries jointly and severally agreed to guarantee and act as surety for the Company's obligation to repay the Original Notes pursuant to a subsidiary guarantee.

On *September 3, 2021,* the Company entered into (*1*) the Omnibus Amendment to the Secured Promissory Notes (the "Amended Notes") with Mr. Pickens, in connection with the Original Notes, and (*2*) the Omnibus Amendment to the Security Agreements (the "Amended Security Agreements", and together with the Amended Notes, the "Amendments") with the Subsidiaries, in connection with the Original Security Agreements. Pursuant to the Amendments, (a) the principal amount of $1.0 million and accrued interest of $172 thousand on the *2020* Note was paid in full and the *2020* Note was canceled, and (b) $1.0 million of the principal amount and $330 thousand of accrued interest on the *2019* Note was paid and the maturity date on the remaining balance of $500 thousand of the *2019* Note was extended to *September 5, 2022 (*the "Amended Maturity Date").

In addition, the Subsidiaries jointly and severally agreed to guarantee and act as surety for the Company's obligation to repay the remaining balance on the *2019* Note pursuant to subsidiary guarantees, dated *September 5, 2019* and *February 13, 2020,* as amended by the Omnibus Amendments to Subsidiary Guarantees, dated *August 24, 2020* and *September 3, 2021,* respectively (the Omnibus Amendment to Subsidiary Guarantees dated *September 3, 2021,* the "Amended Subsidiary Guarantee"). The Subsidiary Guarantee with respect to the *2020* Note was also canceled by the Amended Subsidiary Guarantee due to the *2020* Note being repaid in full.

On *September 5, 2022,* the *2019* Note matured and the principal amount of $500 thousand and accrued interest of $55 thousand was paid in full and the *2019* Note was canceled. With the cancelation of the *2019* Note, the Amended Subsidiary Guarantee was terminated and the Subsidiaries' Collateral was released.

**(*10*) Business Risk and Credit Risk Concentration Involving Cash** 

For the *three* and *six* months ended *December 31, 2022* and *December 31, 2021,* the Company had three customers that comprised materially all of the Company's revenue. Additionally, the material amount of trade receivables was comprised of *one* customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

The Company maintains funds in bank accounts that *may* exceed the limit insured by the Federal Deposit Insurance Corporation of $250 thousand per depositor. The risk of loss attributable to these uninsured balances is mitigated by depositing funds in what we believe to be high credit quality financial institutions. The Company has *not* experienced any losses in such accounts.

**(*11*) Stock-Based Compensation** 

***Stock Option Activity Summary***

The Company's stock option activity for the *six* months ended *December 31, 2022* is as follows:

---

| | | |
|:---|:---|:---|
|  | ***Shares*** | ***Weighted Average Exercise Price*** |
| **Outstanding at June 30, 2022** | **34284** | $**40.41** |
| Granted | 5162 | 13.20 |
| Exercised |  |  |
| Canceled or expired | (2414) | 174.08 |
| **Outstanding at December 31, 2022** | **37032** | $**27.91** |

---

The aggregate intrinsic value of options exercisable at *December 31, 2022* was $0, as the fair value of the Company's common stock is less than the exercise prices of these options. The remaining stock-based compensation expense of $446 thousand related to stock options will be recognized over a weighted-average period of 2.33 years.

The table below details the Company's stock options outstanding as of *December 31, 2022*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Range of exercise prices*** | ***Number Outstanding*** | ***Options Outstanding Weighted-Average Remaining Contractual Life (Years)*** | ***Weighted-Average Exercise Price*** | ***Number Exercisable*** | ***Options Exercisable Weighted-Average Exercise Price*** |
| $13.20 - 19.20 | 34361 | 9.35 | $18.30 |  | $— |
| $55.50 - 84.90 | 431 | 5.76 | 62.22 | 431 | 62.22 |
| $159.00 - 175.50 | 2240 | 4.36 | 168.82 | 2240 | 168.82 |
| $**13.20 - 175.50** | **37032** | **9.00** | $**27.91** | **2671** | $**151.62** |

---

Compensation costs recognized related to stock option awards were $48 thousand and $0 for each of the *three* months ended *December 31, 2022*, and *2021*. Compensation costs recognized related to stock option awards were $94 thousand and $1 thousand for each of the *six* months ended *December 31, 2022* and *2021*.

***Restricted Stock***

The Company's restricted stock activity for the *six* months ended *December 31, 2022*, is as follows:

---

| | | |
|:---|:---|:---|
|  | ***Shares*** | ***Weighted Average Grant Date Fair Value*** |
| **Outstanding at June 30, 2022** | **75873** | $**39.00** |
| Granted |  |  |
| Vested |  |  |
| Canceled or expired | (55) | 60.60 |
| **Outstanding at December 31, 2022** | **75818** | $**38.93** |

---

Stock compensation expenses related to restricted stock were $356 thousand and $439 thousand for the *three* months ended *December 31, 2022*, and *2021*, respectively. Stock compensation expenses related to restricted stock were $697 thousand and $797 thousand for the *six* months ended *December 31, 2022* and *2021*, respectively. The remaining stock-based compensation expense of $2.0 million related to restricted stock awards granted will be recognized over a weighted-average period of 2.13 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

**(*12*) Income Taxes** 

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than *not* to be realized. As of *December 31, 2022*, the Company established a valuation allowance against all of its net deferred tax assets.

For the *three* months ended *December 31, 2022* and *2021,* the Company incurred pre-tax losses in the amount of $2.4 million and $2.2 million, respectively. For the *six* months ended *December 31, 2022* and *2021*, the Company incurred pre-tax losses in the amount of $4.9 million and $4.2 million, respectively. The total effective tax rate was approximately 0% for each of the *three* and *six* months ended *December 31, 2022* and *2021.*

For each of the *six* months ended *December 31, 2022* and *2021,* the Company's effective tax rate differed from the federal statutory rate of 21%, primarily due to the valuation allowance placed against its net deferred tax assets.

The Inflation Reduction Act and the Chips and Science Act were enacted in *August 2022.* There is *no* material impact to the Company from these new tax laws.

FASB ASC *740,* "Income Taxes" addresses the accounting for uncertainty in income tax recognized in an entity's financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. The Company currently has approximately $400 thousand of uncertain tax positions as of *December 31, 2022*, all of which are accounted as contra-deferred tax assets. The Company does *not* expect any significant changes to its uncertain tax positions in the coming *12* months.

Loss carryovers are generally subject to modification by tax authorities until *three* years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended *2003* through present for federal purposes and fiscal years ended *2006* through present for state purposes.

**(*13*) Commitments and Contingencies** 

The Company is subject to various lawsuits and other claims in the normal course of business. In addition, from time to time, the Company receives communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which the Company operates.

The Company establishes reserves for the estimated losses on specific contingent liabilities, for regulatory and legal actions where the Company deems a loss to be probable and the amount of the loss can be reasonably estimated. In other instances, the Company is *not* able to make a reasonable estimate of liability because of the uncertainties related to the outcome or the amount or range of potential loss.

***Litigation, Investigations, and Audits***

On *April 15, 2021,* a putative stockholder of the Company commenced a class action and derivative lawsuit in the Delaware Court of Chancery, Stein v. Pickens, et al., C.A. *No. 2021*-*0322*-JRS (the "Stein Action"), in which it was alleged, among other things, that the Company improperly included broker non-votes in the tabulation of votes counted in favor to approve an amendment to the Company's Certificate of Incorporation (the *"2020* Certificate Amendment") and, thus the *2020* Certificate Amendment was defective. The Company investigated those allegations and does *not* believe that the filing and effectiveness of the *2020* Certificate Amendment was either invalid or ineffective. Nevertheless, to resolve any uncertainty, on *April 30, 2021,* the Company filed a validation proceeding in the Delaware Court of Chancery, In re Astrotech Corporation, C.A. *No. 2021*-*0380*-JRS, pursuant to Section *205* of the Delaware General Corporation Law. On *October 6, 2021,* the Delaware Court of Chancery granted the Company's request and confirmed and validated the *2020* Certificate Amendment. Thereafter, a settlement in principle was reached with the Plaintiffs in the Stein Action and the parties to the Stein Action presented the settlement to the Court for approval. The Company is currently awaiting a Court decision.

Further information regarding the Stein Action and the Section *205* Action is provided in the Schedule *14A* proxy statement amendment and supplement filed by the Company with the SEC on *April 29, 2021.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

**(*14*) Segment Information** 

The Company has determined that it does *not* meet the criteria of ASC *280* "Segment Reporting" because the Company's subsidiaries represent Company brands that leverage the same core technology rather than independent operating segments. Furthermore, restatement of prior results is *not* necessary as they would mirror the consolidated results.

**(*15*) Impact of COVID-*19* Pandemic**

To date, the Company has seen delays with respect to the TSA certification process and parts of its supply chain, particularly the impact of the global semiconductor and electronics shortage, which has now resulted in product pricing inflation. In addition, although passenger demand for air travel has rebounded, the overall recovery of the airline industry and ancillary services remains uncertain and is dependent upon, among other things, public health impacts of new COVID-*19* variants and subsequent recommendations and restrictions provided by federal, state and local authorities.

The Company continues to manage production, secure alternative supplies, and take other proactive actions. The Company believes that it will be able to pass the inflation caused by raw materials shortages and increased shipping costs to its customers by increasing the price of its instruments. If supply chain shortages become more severe or longer term in nature, the Company's business and results of operations could be adversely impacted; however, the Company does *not* expect this issue to materially adversely affect its liquidity position. The long-term impact of the COVID-*19* pandemic on the Company's business *may not* be fully reflected until future periods.

***CARES Act***

On *March 27, 2020,* the CARES Act was enacted. The CARES Act, among other things, includes provisions relating to refundable payroll taxes, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The most significant relief measures which the Company qualified for were a loan pursuant to the Paycheck Protection Program for which the Company has received full forgiveness, alternative minimum tax credit refunds, employee retention credit, and payroll tax deferral. The payroll tax deferral was effective from the enactment date through *December 31, 2020,* and 100% of the deferred amount has been paid as of *December 31, 2022.* The deferred payroll taxes were recorded within accrued liabilities on the condensed consolidated balance sheets.

The Company will continue to assess the treatment of the CARES Act to the extent additional guidance and regulations are issued, the further applicability of the CARES Act to the Company, and the potential impacts on the business.

**(*16*) Subsequent Events**

On *January 27, 2023,* the Board of Directors (the "Board") of the Company increased the size of the Board from *four* to *five* directors and appointed Bob McFarland as a director of the Company, effective as of *January 27, 2023.* The Board has determined that Mr. McFarland is independent in accordance with Nasdaq rules. Mr. McFarland has *not* yet been named to a Board committee. In connection with his appointment, Mr. McFarland was granted 2,150 restricted shares of the Company's common stock under the Company's *2021* Omnibus Equity Incentive Plan, vesting in *three* equal annual installments on *January 27, 2024, January 27, 2025,* and *January 27, 2026.* Mr. McFarland will receive the standard compensation package for the Company's non-employee directors as described in the section entitled "Director Compensation" in the Company's definitive proxy statement on Schedule *14A* filed with the Securities and Exchange Commission on *September 26, 2022.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "plans," "believes," "estimates," "expects," "intends," and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:

● The impact of the COVID-19 pandemic on the global economy, including the possibility of a global recession, and more specifically the impact to our business, partners, suppliers, customers, and employees;

● Our ability to successfully pursue our business plan and execute our strategy, including our collaboration with Cleveland Clinic;

● The effect of economic and political conditions in the United States or other nations that could impact our ability to sell our products and services or gain customers;

● Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers;

● The impact of trade barriers imposed by the U.S. government, such as import/export duties and restrictions, tariffs and quotas, and potential corresponding actions by other countries in which we conduct our business;

● Technological difficulties and potential legal claims arising from any technological difficulties;

● The risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation;

● Uncertainty in government funding and support for key programs, grant opportunities, or procurements;

● The impact of competition on our ability to win new contracts;

● Our ability to meet technological development milestones and overcome development challenges; and

● Our ability to successfully identify, complete and integrate acquisitions.

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our 2022 Annual Report on Form 10-K, elsewhere in this Quarterly Report on Form 10-Q, or those discussed in other documents we filed with the SEC. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the SEC or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

[**Table of Contents**](#toc)

**ITEM 2. MANAGEMENT**'**S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report.*

**Business Overview**

Astrotech Corporation (Nasdaq: ASTC) ("Astrotech," the "Company," "we," "us," or "our"), a Delaware corporation organized in 1984, is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology.

Our efforts are focused on commercializing our platform mass spectrometry technology through our wholly-owned subsidiaries:

● Astrotech Technologies, Inc. ("ATI") owns and licenses intellectual property related to the Astrotech Mass Spectrometer Technology™ (the "AMS Technology").

● 1<sup>st</sup> Detect Corporation ("1<sup>st</sup> Detect") is a manufacturer of explosives trace detectors capable of also detecting narcotics. It was developed for use at airports, cargo and other secured facilities, and borders worldwide. 1<sup>st</sup> Detect holds an exclusive AMS Technology license from ATI for air passenger and cargo security applications.

● AgLAB, Inc. ("AgLAB") is developing a series of mass spectrometers for use in the hemp and cannabis market with initial focus on optimizing yields in the extraction and distillation processes. AgLAB holds an exclusive AMS Technology license from ATI for agriculture applications.

● BreathTech Corporation ("BreathTech") is developing a breath analysis tool to screen for volatile organic compound ("VOC") metabolites found in a person's breath that could indicate they may have a bacterial or viral infection. BreathTech holds an exclusive AMS Technology license from ATI for breath analysis applications.

**Our Business Units**

***Astrotech Technologies, Inc.***

ATI owns and licenses the AMS Technology, the platform mass spectrometry technology originally developed by 1st Detect. Long recognized as the gold standard in chemical detection, mass spectrometry has historically been too costly, bulky, and cumbersome. In contrast, the AMS Technology has been designed to be inexpensive, smaller, and easier to use when compared to traditional mass spectrometers. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 21 granted patents and one additional patent in process along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to three wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1<sup>st</sup> Detect for use in the security and detection market, to AgLAB for use in the agriculture market, and to BreathTech for use in breath analysis applications.

ATI has contracted with Sanmina Corporation ("Sanmina"), a leading contract manufacturer with a worldwide presence, to manufacture our mass spectrometer products. Leveraging their expertise, Sanmina has helped to improve the manufacturability and reliability of our systems.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

[**Table of Contents**](#toc)

***1<sup>st</sup> Detect Corporation***

1<sup>st</sup> Detect, a licensee of ATI for the security and detection market, has developed the TRACER 1000™, the world's first mass spectrometry ("MS") based explosives trace detector ("ETD") certified by the European Civil Aviation Conference ("ECAC"). The TRACER 1000 was designed to outperform the ETDs currently used at airports, cargo and other secured facilities, and borders worldwide. We believe that some ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry ("IMS"). We further believe that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument's performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000's detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.

In order to sell the TRACER 1000 to airport and cargo security customers in the European Union and certain other countries, we obtained ECAC certification. We are currently selling the TRACER 1000 to customers who accept ECAC certification. As of December 31, 2022, we have deployed the TRACER 1000 in approximately 21 locations in 14 countries throughout Europe and Asia.

In the United States, we are working with the U.S. Transportation Security Administration ("TSA") towards air cargo certification. On March 27, 2018, we announced that the TRACER 1000 was accepted into TSA's Air Cargo Screening Technology Qualification Test ("ACSQT") and, on April 4, 2018, we announced that the TRACER 1000 was beginning testing with the TSA for passenger screening at airports. On November 14, 2019, we announced that the TRACER 1000 had been selected by the TSA's Innovation Task Force to conduct live checkpoint screening at Miami International Airport. With similar protocols as ECAC testing, we have received valuable feedback from all programs. Following ECAC certification and our early traction within the cargo market, testing for cargo security continued with the TSA. With the onset of the COVID-19 pandemic, all testing within the TSA was put on hold; however, we resumed cargo testing during the summer of 2020, and we subsequently announced on September 9, 2020, that the TRACER 1000 passed the non-detection testing portion of the TSA's ACSQT. Due to delays caused by COVID-19, TSA cargo detection testing is ongoing, but has proceeded much more slowly than originally anticipated. As a result, efforts are primarily focused on our other opportunities. TSA cargo detection testing is the final step to be listed on the Air Cargo Screening Technology List as an "approved" device. If approved, the TRACER 1000 will be approved for cargo sales in the United States.

***AgLAB Inc.***

AgLAB, an exclusive licensee of ATI for the agriculture market, has developed the AgLAB 1000™ series of mass spectrometers for use in the hemp and cannabis markets with initial focus on optimizing yields in the distillation process. The AgLAB product line is a derivative of our core AMS Technology. The AMS Technology provides a significant competitive advantage due to its small size, rugged design, quick analysis, and ease of use. AgLAB has continued to conduct field trials to demonstrate that the AgLAB 1000-D2™ can be used in the distillation process to significantly improve the processing yields of tetrahydrocannabinol ("THC") and cannabidiol ("CBD") oil during distillation. As part of our growth plan, we also plan to launch a family of "process control" methods and solutions that we believe could be valuable additions to many nutraceutical distillation laboratories.

During the first quarter of fiscal year 2023, we began our first production run of the AgLAB 1000-D2 and sales efforts are currently underway.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

[**Table of Contents**](#toc)

***BreathTech Corporation***

BreathTech, an exclusive licensee of ATI for use in breath analysis applications, is developing the BreathTest-1000™, a breath analysis tool to screen for VOC metabolites found in a person's breath that could indicate they may have a bacterial or viral infection. We believe that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

In June 2022, we expanded our existing study that initially focused on COVID-19 with Cleveland Clinic to use the BreathTest-1000 to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus ("RSV"), carriage of Staphylococcus aureus, and Clostridioides difficile ("C. diff") infections.

BreathTech recently contracted with a clinical research firm to assist in procuring breath samples collected from patients. These samples are being used to further develop the library of the BreathTest-1000. Preliminary results have shown that the BreathTest-1000 can discriminate between background breath and the disease VOCs.

***Trends and Uncertainties - COVID-19***

To date, we have seen delays with respect to the TSA certification process and parts of its supply chain, particularly the impact of the global semiconductor and electronics shortage, which has now resulted in product pricing inflation. In addition, although passenger demand for air travel has rebounded, the overall recovery of the airline industry and ancillary services remains uncertain and is dependent upon, among other things, public health impacts of new COVID-19 variants and subsequent recommendations and restrictions provided by federal, state and local authorities.

We continue to manage production, to secure alternative supplies, and to take other proactive actions. We believe that we will be able to pass the inflation caused by raw materials shortages and increased shipping costs to our customers by increasing the price of our instruments. If supply chain shortages become more severe or longer term in nature, our business and results of operations could be adversely impacted; however, we do not expect this issue to materially adversely affect its liquidity position. The long-term impact of the COVID-19 pandemic on our business may not be fully reflected until future periods.

**Critical Accounting Estimates**

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP"). The preparation of these financial statements requires us to make estimates and judgments that directly affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. A critical accounting estimate is one that involves a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management continuously evaluates its critical accounting policies and estimates, including those used in evaluating the recoverability of long-lived assets, recognition of revenue, valuation of inventory, and the recognition and measurement of loss contingencies, if any. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates as set forth in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended June 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

[**Table of Contents**](#toc)

**Results of Operations**

**Three months ended December 31, 2022, compared to three months ended December 31, 2021**:

Selected consolidated financial data for the quarters ended December 31, 2022, and 2021 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| **(In thousands)** | **2022** | **2021** |
| Revenue | $263 | $561 |
| Cost of revenue | 155 | 441 |
| **Gross profit** | **108** | **120** |
| **Gross margin** | **41%** | **21%** |
| Operating expenses: |  |  |
| Selling, general and administrative | 1558 | 1728 |
| Research and development | 1364 | 652 |
| **Total operating expenses** | **2922** | **2380** |
| **Loss from operations** | **(2814)** | **(2260)** |
| Other income and expense, net | 396 | 80 |
| Income tax benefit |  |  |
| **Net loss** | $**(2418)** | $**(2180)** |

---

***Revenue*** – Total revenue decreased by $298 thousand during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022. In the second quarter of fiscal 2023, the majority of the revenue was related to sales of our TRACER 1000 to two new customers, in addition to ongoing consumable and recurring maintenance services. In the second quarter of fiscal 2022, all revenue was related to the sales of our TRACER 1000 to an airport security checkpoint customer and to DHL (Deutsche Post AG), along with ongoing sales of consumables and recurring maintenance services. The decrease in revenue is primarily the result of Astrotech shifting its sales efforts from the volatile ETD market and concentrating on commercializing, marketing, and selling the AgLAB 1000-D2. We believe that the AgLAB market should provide for a more profitable opportunity compared to the commoditized ETD market.

***Cost of Revenue*** – Gross profit is comprised of revenue less cost of revenue. In the second quarter of fiscal 2023 and 2022, cost of revenue was comprised of labor, materials, shipping, and warranty reserve related to the sale of TRACER 1000 units. Cost of revenue decreased $286 thousand during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022 due to the decrease in revenue as described above. Gross margin increased by 20% in the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022 due to a higher proportion of recurring revenue.

***Operating Expenses*** – Operating expenses increased $542 thousand, or 22.8%, during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022. Significant changes to operating expenses include the following:

● Selling, general and administrative expenses decreased $170 thousand, or 9.8%, during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022, due to decreases in legal expenses related to the derivative litigation, property tax, and timing of regulatory reporting.

● Research and development expenses increased $712 thousand, or 109.2%, during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022, largely driven by increases in expenses related to cross-platform improvements to our technology, field trials and further development and refinement of our AgLAB product, increased headcount, as well as contracting an additional clinical research firm to accelerate the collection of samples for building the BreathTech library.

***Other income and expense, net*** – Other income and expense, net increased by $316 thousand during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022, due to more income earned on capital-preservation investments as interest rates have increased.

***Income Taxes*** – ****Income tax benefit did not change during the second quarter of fiscal 2023, compared to the second quarter of fiscal 2022. The realization of tax benefits depends on the existence of future taxable income. Pursuant to Accounting Standards Codification ("ASC") 740 "Income Taxes", a valuation allowance has been established on all of our deferred tax assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

[**Table of Contents**](#toc)

**Six months ended December 31, 2022, compared to six months ended December 31, 2021**:

Selected consolidated financial data for the six months ended December 31, 2022, and 2021 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| **(In thousands)** | **2022** | **2021** |
| Revenue | $301 | $748 |
| Cost of revenue | 187 | 616 |
| **Gross profit** | **114** | **132** |
| **Gross margin** | **38%** | **18%** |
| Operating expenses: |  |  |
| Selling, general and administrative | 3200 | 3154 |
| Research and development | 2492 | 1291 |
| **Total operating expenses** | **5692** | **4445** |
| **Loss from operations** | **(5578)** | **(4313)** |
| Other income and expense, net | 631 | 104 |
| Income tax benefit |  |  |
| **Net loss** | $**(4947)** | $**(4209**) |

---

***Revenue*** – Total revenue decreased by $447 thousand during the fiscal year 2023, compared to the fiscal year 2022. In the fiscal year 2023, all revenue was comprised of TRACER 1000 unit sales and rentals, as well as ongoing sales of consumables and recurring maintenance services for the TRACER 1000. In the fiscal year 2022, all revenue was related to the sales of our TRACER 1000 to an airport security checkpoint customer as well as DHL (Deutsche Post AG). The decrease in revenue is primarily the result of Astrotech shifting its sales efforts from the volatile ETD market and concentrating on commercializing, marketing, and selling the AgLAB 1000-D2. We believe that the AgLAB market should provide for a more profitable opportunity compared to the commoditized ETD market.

***Cost of Revenue*** – Gross profit is comprised of revenue less cost of revenue. In the six months ended December 31, 2022 and 2021, cost of revenue was comprised of labor, materials, shipping, and warranty reserve related to the sale of TRACER 1000 units. Cost of revenue decreased $429 thousand during the fiscal year 2023, compared to fiscal year 2022, due to the decrease in revenue as described above. Gross margin increased by 20% in the fiscal year 2023, compared to the fiscal year 2022 due to a higher proportion of recurring revenue.

***Operating Expenses*** – Operating expenses increased $1.2 million, or 28.1%, during the six months ended December 31, 2022, compared to the six months ended December 31, 2021. Significant changes to operating expenses include the following:

● Selling, general and administrative expenses remained consistent during the six months ended December 31, 2022, compared to the six months ended December 31, 2021.

● Research and development expenses increased $1.2 million, or 93.0%, during the six months ended December 31, 2022, compared to the six months ended December 31, 2021, largely driven by increases in expenses related to cross-platform improvements to our technology, field trials and further development and refinement of our AgLAB product, increased headcount, purchases of machinery and equipment, as well as contracting an additional clinical research firm to accelerate the collection of samples for building the BreathTech library.

***Other income and expense, net*** – Other income and expense, net increased $527 thousand during the six months ended December 31, 2022 compared to the six months ended December 31, 2021 driven by more income earned on short-term, capital-preservation investments as interest rates have increased and a reduction of interest expense from the partial payment of related party notes in September 2021 which was the primary driver of the prior year other income and expense, net.

***Income Taxes*** – ****Income tax benefit did not change during the six months ended December 31, 2022, compared to the six months ended December 31, 2021. The realization of tax benefits depends on the existence of future taxable income. Pursuant to ASC 740, a valuation allowance has been established on all of our deferred tax assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

[**Table of Contents**](#toc)

**Liquidity and Capital Resources**

**Cash Flows**

The following is a summary of the change in our cash and cash equivalents:

---

| | | | |
|:---|:---|:---|:---|
|  | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| **(In thousands)** | **2022** | **2021** | **Change** |
| Change in cash and cash equivalents: |  |  |  |
| Net cash used in operating activities | $(4255) | $(3484) | $(771) |
| &nbsp;&nbsp;&nbsp; Net cash used in investing activities | (5732) | (264) | (5468) |
| Net cash used in financing activities | (577) | (2018) | 1441 |
| **Net change in cash and cash equivalents** | $**(10564)** | $**(5766)** | $**(4798)** |

---

***Cash and Cash Equivalents***

As of December 31, 2022, we held cash and cash equivalents of $15.9 million, and our working capital was approximately $47.2 million. As of June 30, 2022, we had cash and cash equivalents of $26.4 million, and our working capital was approximately $52.3 million. Cash and cash equivalents decreased $10.6 million as of December 31, 2022, compared to June 30, 2022, due to the purchases of short-term time deposit investments as well as continuing operating expenses.

***Operating Activities***

Cash used in operating activities increased $771 thousand for the six months ended December 31, 2022, compared to the six months ended December 31, 2021, due to an increase in prepayments and operating expenses, partially offset by an increase of accounts payable.

***Investing Activities***

Cash used in investing activities increased $5.5 million for the six months ended December 31, 2022, compared to the six months ended December 31, 2021, due to the purchases of short-term time deposit investments.

***Financing Activities***

Cash used in financing activities decreased $1.4 million for the six months ended December 31, 2022, compared to the six months ended December 31, 2021, due to a larger repayment of related party debt in the prior year.

We did not have any material off-balance sheet arrangements as of December 31, 2022.

***Share Repurchase Program***

On November 9, 2022, the Company's Board of Directors authorized a share repurchase program that allows the Company to repurchase up to $1.0 million of the Company's common stock beginning November 17, 2022 and continuing through and including November 17, 2023. The shares may be repurchased from time to time in open market or privately negotiated transactions or by other means in accordance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including management's assessment of the intrinsic value of the Company's common stock, the market price of the Company's common stock, general market and economic conditions, available liquidity, compliance with the Company's debt and other agreements, applicable legal requirements, and other considerations. The exact number of shares to be repurchased by the Company is not guaranteed, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases with available working capital. There were no repurchases of the Company's common stock under the share repurchase program during the three months ended December 31, 2022.

**Liquidity**

During the fiscal year 2021, we successfully completed several public offerings of our common stock, raising net proceeds of approximately $67.6 million which will be used to satisfy our short-term and long-term capital needs. Other than using cash to pay for repurchases of the Company's common stock under the share repurchase program, there have been no material updates to our expectations for our short- and long-term liquidity and operating capital requirements since our Annual Report on Form 10-K for the year ended June 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

[**Table of Contents**](#toc)

**Income Taxes** 

***Provision for Income Tax***

Our effective tax rate is 0% for income tax for the six months ended December 31, 2022, and we expect that our effective tax rate for the full fiscal year 2023 year will be 0%. Based on the weight of available evidence, including net cumulative losses and expected future losses, we have determined that it is more likely than not that our U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets.

In general, if we experience a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change net operating loss ("NOL") carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code. Generally, U.S. state laws have laws similar to Internal Revenue Code Section 382. The annual limitation generally is determined by multiplying the value of the Company's stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforward before utilization.

We file U.S. federal and state income tax returns. We are not currently subject to any income tax examinations. Dating back to June 2002, we have net operating loss carryovers, which generally allows all tax years to remain open to income tax examinations for all years for which there are loss carryforwards.

***Uncertain Tax Positions***

We recognize the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. We currently have approximately $400 thousand of uncertain tax positions as of December 31, 2022, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.

***Income Taxes***

There is $0 provision for income taxes during each of the three and six months ended December 31, 2022 and 2021.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable to smaller reporting companies.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. Management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures were effective as of December 31, 2022 at the reasonable assurance level.

**Changes in Internal Controls over Financial Reporting**

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

[**Table of Contents**](#toc)

**PART II: OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

On April 15, 2021, a putative stockholder of the Company commenced a class action and derivative lawsuit in the Delaware Court of Chancery, Stein v. Pickens, et al., C.A. No. 2021-0322-JRS (the "Stein Action"), in which it was alleged, among other things, that the Company improperly included broker non-votes in the tabulation of votes counted in favor to approve an amendment to the Company's Certificate of Incorporation (the "2020 Certificate Amendment") and, thus the 2020 Certificate Amendment was defective. The Company investigated those allegations and does not believe that the filing and effectiveness of the 2020 Certificate Amendment was either invalid or ineffective. Nevertheless, to resolve any uncertainty, on April 30, 2021, the Company filed a validation proceeding in the Delaware Court of Chancery, In re Astrotech Corporation, C.A. No. 2021-0380-JRS, pursuant to Section 205 of the Delaware General Corporation Law. On October 6, 2021, the Delaware Court of Chancery granted the Company's request and confirmed and validated the 2020 Certificate Amendment. Thereafter, a settlement in principle was reached with the Plaintiffs in the Stein Action and the parties to the Stein Action presented the settlement to the Court for approval. The Company is currently awaiting a Court decision.

Further information regarding the Stein Action and the Section 205 Action is provided in the Schedule 14A proxy statement amendment and supplement filed by the Company with the SEC on April 29, 2021.

**ITEM 1A. RISK FACTORS**

Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our Form 10-K and our Form 10-Qs, the occurrence of any one of which could have a material adverse effect on our actual results.

Except as set forth below, there have been no material changes to the risk factors and other cautionary statements described under the heading "Item 1A. Risk Factors" included in our Form 10-K for the fiscal year ended June 30, 2022:

***There can be no assurance that we will repurchase shares of our common stock at all or in any particular amounts.***

The stock markets in general have experienced substantial price and trading fluctuations, which have resulted in volatility in the market prices of securities that often are unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the trading price of our common stock. Price volatility over a given period may also cause the average price at which we repurchase our own common stock to exceed the stock's price at a given point in time. In addition, significant changes in the trading price of our common stock and our ability to access capital on terms favorable to us could impact our ability to repurchase shares of our common stock. The timing and amount of any repurchases will be determined by the Company's management based on its evaluation of market conditions, capital allocation alternatives and other factors beyond our control. Our share repurchase program may be modified, suspended, extended or terminated by the Company at any time and without notice.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On November 9, 2022, the Company's Board of Directors authorized a share repurchase program that allows the Company to repurchase up to $1.0 million of the Company's common stock beginning November 17, 2022 and continuing through and including November 17, 2023. There were no repurchases of the Company's common stock under the share repurchase program during the three months ended December 31, 2022.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURE**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

**ITEM 6. EXHIBITS**

---

| | | |
|:---|:---|:---|
| **Exhibit** <br> **No.** | **Description** | **Incorporation by**<br> **Reference** |
| 3.1 | [<u>Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware.</u>](http://www.sec.gov/Archives/edgar/data/1001907/000100190717000090/ex31decharter.htm) | Exhibit 3.1 to Form 8-K filed on December 28, 2017. |
| 3.2 | [<u>Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant'</u><u>s Form 8-K filed with the Securities and Exchange Commission on December 28, 2017).</u>](http://www.sec.gov/Archives/edgar/data/1001907/000100190717000090/ex32debylaws.htm) | Exhibit 3.2 to Form 8-K filed on December 28, 2017. |
| 3.3 | [<u>Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware.</u>](http://www.sec.gov/Archives/edgar/data/1001907/000100190717000090/ex33certofdesignations.htm) | Exhibit 3.3 to Form 8-K filed on December 28, 2017. |
| 3.4 | [<u>Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019.</u>](http://www.sec.gov/Archives/edgar/data/1001907/000156459019012437/astc-ex32_7.htm) | Exhibit 3.2 to Form 8-K filed on April 23, 2019. |
| 3.5 | [<u>Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.</u>](http://www.sec.gov/Archives/edgar/data/1001907/000156459020031627/astc-ex31_6.htm) | Exhibit 3.1 to Form 8-K filed on July 1, 2020. |
| 3.6 | [<u>Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.</u>](http://www.sec.gov/Archives/edgar/data/0001001907/000156459021050598/astc-ex31_6.htm) | Exhibit 3.1 to Form 8-K filed on October 12, 2021. |
| 3.7 | [Third Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.](http://www.sec.gov/Archives/edgar/data/1001907/000143774922027965/ex_450105.htm) | Exhibit 3.1 to Form 8-K filed on November 23, 2022. |
| 4.1 | [Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, dated as of December 21, 2022.](http://www.sec.gov/Archives/edgar/data/1001907/000143774922029528/ex_458231.htm) | Exhibit 4.1 to Form 8-K filed on December 21, 2022. |
| 31.1 | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.](ex_462680.htm) | Filed herewith. |
| 31.2 | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.](ex_462681.htm) | Filed herewith. |
| 32.1 | [Certification pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934.](ex_462682.htm) | Furnished herewith. |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Filed herewith. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed herewith. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith. |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | Filed herewith. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith. |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2022, has been formatted in Inline XBRL. |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | Astrotech Corporation |
| Date: February 13, 2023 | /s/ Jaime Hinojosa |
|  | Jaime Hinojosa |
|  | Chief Financial Officer, Treasurer and Secretary<br> (Principal Financial and Accounting Officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

## Exhibit 31.1

**Exhibit 31.1**

**Certification of Chief Executive Officer**

**Section 302 Certification**

I, Thomas B. Pickens III, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Astrotech Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date: February 13, 2023 | /s/ Thomas B. Pickens III |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thomas B. Pickens III |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer<br> (principal executive officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**Certification of Chief Financial Officer**

**Section 302 Certification**

I, Jaime Hinojosa, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Astrotech Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date: February 13, 2023 | /s/ Jaime Hinojosa |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaime Hinojosa |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Financial Officer<br> (principal financial officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Thomas B. Pickens III, the Chief Executive Officer, and Jaime Hinojosa, the Chief Financial Officer, of Astrotech Corporation (the "Company"), hereby certify, that, to their knowledge:

1. The Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Date: February 13, 2023 |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; /s/ Thomas B. Pickens III |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Thomas B. Pickens III |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer<br> (principal executive officer) |
|  | &nbsp;&nbsp;&nbsp;&nbsp; /s/ Jaime Hinojosa |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Jaime Hinojosa |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Chief Financial Officer<br> (principal financial officer) |

---